1. Medtech Insight
  2. >>Device Area
  3. >>Oncology

BTG Set To Launch First Radiopaque Drug-Eluting Bead In The EU

 
• By Reed Miller

DC Bead Lumi is designed to be loaded with doxorubicin or irinotecan to treat liver cancer while showing the treating physician where it is to improve control of transarterial chemoembolization procedures.

BTG PLC’s DC Bead LUMI is the first radiopaque drug-eluting bead available in the EU now that it has received a CE mark, the company announced March 7.

DC Bead LUMI, which builds on the company’s DC Bead technology, can be loaded with doxorubicin or irinotecan for transarterial chemoembolization procedures to treat hepatocellular carcinoma and malignant colorectal cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Oncology

More from Device Area

Pathogen Sharing System Part Of Global Pandemic Agreement

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.